Close Menu

Amgen

On the first day, Amgen detailed the rapid advancement of its KRAS inhibitor and Tempus unveiled an AI device to help oncologists deliver precision oncology. 

The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.

Although a record number of new precision oncology drugs came to market, the pandemic further exposed access gaps that the field is focused on mitigating.

If approved, the drug would be the first targeted therapy available to treat patients with NSCLC harboring KRAS G12C mutations.

The drugmaker will work with McKesson's Ontada to gather real-world data insights on molecular testing and cancer treatment patterns and identify access gaps.

The company said data from the Phase II portion of the CodeBreak-100 study in KRAS-mutated lung cancer patients was positive and may be registrational.

Phase I data at ESMO suggested that the experimental drug may be particularly effective in KRAS G12C-mutated lung and colon cancers.

The Amgen-sponsored Phase Ib study is evaluating the combination in patients with advanced solid tumors characterized by KRAS G12C mutations.

The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.

The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.

Pages